Mammotome Launches Industry's First MR-Compatible Vacuum System for Breast Biopsy
Mammotome, a subsidiary of Danaher Corporation, has recently unveiled its latest innovation in breast care technology: the Mammotome Prima™ MR, a dual vacuum-assisted system specifically designed for use in MRI suites. This first-of-its-kind solution allows procedures to be performed right next to the MRI scanner, greatly enhancing the workflow and coordination between clinicians during breast biopsy procedures.
The Mammotome Prima™ MR system represents a significant advancement in the efficiency of breast biopsies. It features an intuitive design that streamlines the process, allowing for easier use within an MRI environment. Thanks to its improved vacuum capabilities and an 8G gauge needle, this system enables the extraction of larger tissue samples, leading to more accurate diagnoses. Notably, the device's tubes are 75% shorter than those used in traditional systems, which not only simplifies setup and cleanup but also reduces the amount of biohazard waste generated.
One of the standout features of the Mammotome Prima™ MR system is its ability to enhance the focus on patient care. By integrating this advanced technology into the MRI suite, clinicians can direct their attention more fully on the patient, fostering a sense of empathy and understanding during what can be an anxious time. Scott Treml, Vice President and General Manager of Mammotome, emphasizes this innovative approach, stating, "Every innovation we bring to the market reflects our commitment to improving breast care. The Mammotome Prima™ MR system supports clinicians in delivering effective, confident services that ultimately enhance patient care."
After receiving CE marking, the Mammotome Prima™ MR is slated to be utilized in select European countries. The system will be showcased for the first time at the upcoming European Congress of Radiology (ECR) this March, marking a pivotal moment in its global rollout. In 2026, Mammotome plans to extend its reach further across international markets, offering advanced options for healthcare providers.
In conclusion, the Mammotome Prima™ MR system is set to revolutionize the landscape of breast biopsies within MRI suites. Its blend of advanced technology, patient-centered design, and operational efficiency positions it as a game changer in the medical field. As Mammotome continues to prioritize innovations in breast care, it aims to provide healthcare professionals with the tools they need to ensure that every patient receives the best possible care during their treatment processes.
Simplifying Biopsy Procedures
The Mammotome Prima™ MR system represents a significant advancement in the efficiency of breast biopsies. It features an intuitive design that streamlines the process, allowing for easier use within an MRI environment. Thanks to its improved vacuum capabilities and an 8G gauge needle, this system enables the extraction of larger tissue samples, leading to more accurate diagnoses. Notably, the device's tubes are 75% shorter than those used in traditional systems, which not only simplifies setup and cleanup but also reduces the amount of biohazard waste generated.
Focus on Patient Experience
One of the standout features of the Mammotome Prima™ MR system is its ability to enhance the focus on patient care. By integrating this advanced technology into the MRI suite, clinicians can direct their attention more fully on the patient, fostering a sense of empathy and understanding during what can be an anxious time. Scott Treml, Vice President and General Manager of Mammotome, emphasizes this innovative approach, stating, "Every innovation we bring to the market reflects our commitment to improving breast care. The Mammotome Prima™ MR system supports clinicians in delivering effective, confident services that ultimately enhance patient care."
Market Launch and CE Mark Approval
After receiving CE marking, the Mammotome Prima™ MR is slated to be utilized in select European countries. The system will be showcased for the first time at the upcoming European Congress of Radiology (ECR) this March, marking a pivotal moment in its global rollout. In 2026, Mammotome plans to extend its reach further across international markets, offering advanced options for healthcare providers.
Conclusion
In conclusion, the Mammotome Prima™ MR system is set to revolutionize the landscape of breast biopsies within MRI suites. Its blend of advanced technology, patient-centered design, and operational efficiency positions it as a game changer in the medical field. As Mammotome continues to prioritize innovations in breast care, it aims to provide healthcare professionals with the tools they need to ensure that every patient receives the best possible care during their treatment processes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.